Skip to main content
Loading navigation...
Enerzair Breezhaler Inhaler

Enerzair Breezhaler Inhaler

Manufacturer: Novartis Pharmaceuticals UK Limited

£74.99

Prescription required

Enerzair Breezhaler is a prescription-only maintenance treatment for asthma in adults whose asthma is not adequately controlled with a high-dose inhaled corticosteroid and a long-acting bronchodilator, and who have experienced at least one asthma exacerbation in the previous year.

It contains three active ingredients:

  • Indacaterol – a long-acting bronchodilator.

  • Glycopyrronium – a long-acting muscarinic antagonist that helps keep airways open.

  • Mometasone furoate – an inhaled corticosteroid that reduces airway inflammation.

Enerzair Breezhaler is taken regularly to help control asthma symptoms and is not intended for immediate relief of an asthma attack.

Supplied with 30 inhalation capsules and a Breezhaler inhaler device. This presentation does not include the optional electronic monitoring sensor.

Treatment requires appropriate clinical assessment and a valid prescription.

Each delivered dose contains:

  • Indacaterol 114 micrograms

  • Glycopyrronium 46 micrograms

  • Mometasone furoate 136 micrograms

Other ingredients include lactose monohydrate (contains milk proteins), magnesium stearate and capsule-shell ingredients detailed in the patient leaflet.

WhatsApp